Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 0.16
- Piotroski Score 5.00
- Grade Buy
- Symbol (VERV)
- Company Verve Therapeutics, Inc.
- Price $5.02
- Changes Percentage (7.49%)
- Change $0.35
- Day Low $4.60
- Day High $5.09
- Year High $20.12
Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/05/2024
- Fiscal Year End N/A
- Average Stock Price Target $21.50
- High Stock Price Target $30.00
- Low Stock Price Target $13.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$2.87
- Trailing P/E Ratio -1.82
- Forward P/E Ratio -1.82
- P/E Growth -1.82
- Net Income $-200,068,000
Income Statement
Quarterly
Annual
Latest News of VERV
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
A 32-year market vet shares 5 labor market indicators showing the US economy is barreling toward a recession -- putting an overvalued stock market at risk for major declines
The September jobs report exceeded expectations with 254,000 jobs added, but concerns persist. Analyst Jon Wolfenbarger warns of a negative trend in government job growth, signaling potential recessio...
By Business Insider | 2 days ago -
Nymex Overview: Brent Reclaims $80/bbl Mark as Mideast Tensions Remain High -- OPIS
Refined products futures are rising in tandem with crude prices due to concerns over Hurricane Milton's impact on oil production. Traders are cautious amid the potential for Israeli retaliation agains...
By MarketWatch | 1 week ago -
Nymex Overview: Oil Up, Complex Set for Big Weekly Rise on Mideast Conflicts -- OPIS
The U.S. jobs data for September exceeded expectations, causing oil futures to stabilize as it strengthened the U.S. dollar and reduced the likelihood of a significant interest rate cut. Crude prices ...
By MarketWatch | 1 week ago
